Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom Macroglobulinemia

Explore clinical trials studying Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

395 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom Macroglobulinemia trial results

Completed

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00004889

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Cancer Center and Beckman Research Institute, City of Hope Duarte, California, United States
  • Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States
  • Walter Reed Army Medical Center Washington D.C., District of Columbia, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
View Trial Details
Completed

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT00750009

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +106 more
Locations
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01109069

Conditions
B Cell Lymphoma, B-Cell Diffuse Lymphoma, B-cell Chronic Lymphocytic Leukemia, +41 more
Locations
  • Stanford University Stanford, California, United States
  • Stanford, California, United States
  • University of Chicago Chicago, Illinois, United States
  • Boston, Massachusetts, United States
View all 16 locations
View Trial Details
Completed

Treatment for Chronic Pain in Patients With Advanced Cancer

NCT00003687

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +93 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Newfoundland Cancer Treatment and Research Foundation St. John's, Newfoundland and Labrador, Canada
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • McGill University Montreal, Quebec, Canada
View Trial Details
Completed

Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation

NCT00031668

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +30 more
Locations
  • Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Newfoundland Cancer Treatment and Research Foundation St. John's, Newfoundland and Labrador, Canada
  • Cancer Care Ontario-Hamilton Regional Cancer Centre Hamilton, Ontario, Canada
View Trial Details
Completed

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

NCT00918333

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +75 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +42 more
Locations
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details

Related conditions